NXL Stock Forecast: Nexalin Technology, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Nexalin Technology, Inc. is $15. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Nexalin Technology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NXL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NXL, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Mar 2025 | Maxim Group | Upgrade | Buy | $5.00 |
| 5 Dec 2024 | Maxim Group | Downgrade | Hold | — |
| 9 Oct 2024 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NXL.
This page is one stock. Monday covers all of them.
NXL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NXL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 6.2×
- Price / book
- 4.3×
- EV / EBITDA
- —
Cheaper than 18% of US stocks
Cheaper than 21% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 73.2%
- Operating margin
- —
- Net margin
- —
Higher than 85% of US stocks
- Return on equity
- −372.6%
- Return on assets
- −139.5%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nexalin Technology, Inc. has a market value of $1.7M and an enterprise value of $2.1M.
Revenue in the twelve months to 30 June 2026: $217K. The latest quarter shrank 82.8% year on year.
Net income over the same four quarters: −$9.0M, a −4139.4% net margin.
Free cash flow in the twelve months to 30 June 2026: −$6.3M.
Nexalin Technology, Inc. employs 8 people — $27K of revenue per employee.
Data provided by Twelve Data
NXL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NXL’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Nexalin Technology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NXL
What is the NXL stock price forecast for 2026-2027?
The median 12-month analyst price target for Nexalin Technology, Inc. is $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NXL stock a buy right now?
Of the 1 analyst covering Nexalin Technology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nexalin Technology, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NXL?
As at 21 Nov 2026, Nexalin Technology, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
Will NXL stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $15, and Ticker Nerd's factor model ranks Nexalin Technology, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NXL stock forecast for 2030?
No analyst covering Nexalin Technology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $15 over the next 12 months.
What does Nexalin Technology, Inc. do?
Nexalin Technology, Inc. Common Stock represents an equity interest in Nexalin Technology, Inc., a medical device company focused on neurostimulation products for mental health and related neurological conditions. The company develops noninvasive bioelectronic systems designed to deliver targeted stimulation through headset-based and forehead-mounted devices, with applications in areas such as anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, chronic pain, and other brain-health conditions.
About Nexalin Technology, Inc.
Nexalin Technology, Inc. Common Stock represents an equity interest in Nexalin Technology, Inc., a medical device company focused on neurostimulation products for mental health and related neurological conditions. The company develops noninvasive bioelectronic systems designed to deliver targeted stimulation through headset-based and forehead-mounted devices, with applications in areas such as anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, chronic pain, and other brain-health conditions. Nexalin Technology serves clinicians and patients through products intended for use in medical settings and, in some cases, at home under professional guidance. Its product portfolio is centered on neuromodulation therapies that aim to provide drug-free treatment options within the healthcare and medical technology markets. The stock is used by investors to track ownership in a specialized healthcare company operating at the intersection of medical devices, digital health, and neurotechnology.
CEO Mr. Mark White · 8 employees · United States · https://www.nexalin.com